


## Curriculum Vitae

**Petros Christopoulos** Professor, Dr. med.  
d.o.b. December 11th, 1977, in Athens, Germany



### University Education

2019 Habilitation and *venia legendi* for Internal Medicine, Heidelberg University, Germany  
2009 Doctorate in Medicine, Freiburg University, Germany  
1995–2002 Study of Medicine, University of Athens, Greece (Diploma grade "excellent")

### Scientific Career

Since 2022 Professor of Medicine at Heidelberg University  
Since 2019 Head of Scientific Coordination, Thoracic Oncology at Thoraxklinik; DZL PI at TLRC-H  
2019–2022 Assistant Professor of Medicine at Heidelberg University  
2015–present Hematologist/Oncologist, Thoraxklinik/NCT HD; Director: Prof. Dr. Michael Thomas  
2011–2014 Staff Hematologist/Oncologist, Dept. of Hematology/Oncology and Comprehensive Cancer Center, Würzburg University Hospital; Director: Prof. Dr. Hermann Einsele.  
2008–2011 Fellow in Hematology & Medical Oncology, Dept. of Medicine I, Freiburg University Hospital, Germany; Director: Prof. Dr. Dr.h.c. Roland Mertelsmann  
2006–2008 Resident in Internal Medicine, Dept. of Medicine II, Athens University Hospital, Greece  
2004–2006 Research assistant, Freiburg University Hospital, Germany; Mentor: Prof. Dr. Paul Fisch.  
2003–2004 Military service as a military doctor, 401 General Military Hospital, Athens, Greece  
2002–2003 Service as a doctor in a medically underserved area, Tripolis, Greece

### Qualifications

Since 2009 Investigator in phase >30 clinical trials; regular GCP and PI training  
2019 Curricular training and "Baden-Württemberg certificate in Academic Teaching"  
2010/6/21 ESMO certification/MORA recertification (European Society for Medical Oncology)  
2016 last ACLS, PALS, ACLS-EP certification (American Heart Association)  
2015 FELASA Cat. B certificate for animal experimentation  
2014 Board certification in Palliative Care (Zusatzbezeichnung "Palliativmedizin")  
2014 Board certification in General Internal Medicine ("Internist")  
2013 DAG-KBT certificate in Allogeneic Stem Cell Transplantation  
2013 Qualification in Genetic Counseling ("fachgebundene genetische Beratung")  
2013 Board certification in Emergency Medicine (Zusatzbezeichnung "Notfallmedizin")  
2011 Board certification in Internal Medicine, Hematology and Medical Oncology.  
2011 USMLE Step 3 examination (for medical licensure in USA, grade 99;234)  
2005 ECFMG certificate (for residency in USA, Step I grade 99;267, Step II CK 99;246)  
1996 Grosses Deutsches Sprachdiplom (level C2), Goethe Institute and LMU Munich  
1992 Certificate of Proficiency in English (level C2), Cambridge University

### Honors and Awards

2019 Poster Prize (endowed with 500 €), Annual DGHO Meeting 2019 in Berlin.  
2018 Takeda Oncology Research Award (1<sup>st</sup> prize endowed with 30,000 €)  
2009–2013 Kontoleonos Scholarship from the University of Athens for training abroad.  
1996/7/9 IKY Scholarship due to outstanding performance as a medical student.  
1995 – 2002 Papadakis Scholarship from the University of Athens.  
1995 2<sup>nd</sup> prize in the Greek National Senior High School Physics Competition, and "Honourable Mention" in the XXVI International Physics Olympiad (Canberra, Australia).  
1995 3<sup>rd</sup> prize in the Greek National Senior High School Chemistry Competition.

### Citation Record

Total citations: 1,717; h-index: 22; h-index since 2017: 21 (Google Scholar August 12<sup>th</sup>, 2022)

## Top-10 selected Publications

**Christopoulos P**, Kluck K, Kirchner M, Lüders H *et al.* The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. **Eur J Cancer** 2022 Jul;170:106-118. doi: [10.1016/j.ejca.2022.04.020](https://doi.org/10.1016/j.ejca.2022.04.020).

Benesova K\*, Kraus F\*, Carvalho R, Lorenz H, Hörth C, Günther J, Klika K, Graf J, Diekmann L, Schank T, **Christopoulos P**, Hassel J, Lorenz HM, Souto-Carneiro M. Distinct immune-effector and metabolic profile of CD8 + T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors. **Ann Rheum Dis** 2022 Aug 3;annrheumdis-2022-222451. doi: [10.1136/ard-2022-222451](https://doi.org/10.1136/ard-2022-222451) (\*equal contribution).

Dietz S\*, **Christopoulos P\***, Yuan Z, et al. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. **EBioMedicine** 2020;62:103103. doi: [10.1016/j.ebiom.2020.103103](https://doi.org/10.1016/j.ebiom.2020.103103) (\*equal contribution)

**Christopoulos P**, Kirchner M, Roeper J *et al.* Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing. **Lung Cancer** 2020;148:105-112. doi: [10.1016/j.lungcan.2020.08.007](https://doi.org/10.1016/j.lungcan.2020.08.007).

**Christopoulos P**, Kirchner M, Bozorgmehr F *et al.* Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma. **Int J Cancer** 2019 Jan 1;144(1):190-199. doi: [10.1002/ijc.31893](https://doi.org/10.1002/ijc.31893).

**Christopoulos P**, Schneider M, Bozorgmehr F, Kuon J *et al.* Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. **Lung Cancer** 2018 May;119:48-55. doi: [10.1016/j.lungcan.2018.03.002](https://doi.org/10.1016/j.lungcan.2018.03.002).

**Christopoulos P**, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I *et al.* EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancer. **Int J Cancer**. 2018 Jun 15;142(12):2589-2598. doi: [10.1002/ijc.31275](https://doi.org/10.1002/ijc.31275).

**Christopoulos P**, Engel-Riedel W, Grohé C, Kropf-Santhen C *et al.* Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. **Ann Oncol**. 2017 Aug 1;28(8):1898-1902. doi: [10.1093/annonc/mdx268](https://doi.org/10.1093/annonc/mdx268).

**Christopoulos P**, Dopfer EP, Malkovsky M, Esser RP, Schaefer HE, Marx A, Kock S, Rupp N, Lorenz MR, Schwarz K, Harder J, Martin SF, Werner M, Bogdan C, Schamel WW, Fisch P. A novel thymoma-associated immunodeficiency with increased naive T cells and reduced CD247 expression. **J Immunol**. 2015 Apr 1;194(7):3045-53. doi: [10.4049/jimmunol.1402805](https://doi.org/10.4049/jimmunol.1402805).

**Christopoulos P**, Pfeifer D, Bartholomé K, Follo M, Timmer J, Fisch P, Veelken H. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. **Blood** 2011, 117(4):3836-46. doi: [10.1182/blood-2010-07-299321](https://doi.org/10.1182/blood-2010-07-299321).

**Christopoulos P**, Follo M, Fisch P, Veelken H. The peripheral helper T-cell repertoire in untreated indolent B-cell lymphomas: evidence for antigen-driven lymphomagenesis. **Leukemia** 2008, 22(10):1952-4. doi: [10.1038/leu.2008.82](https://doi.org/10.1038/leu.2008.82).